Fabre-Kramer Submits NDA Amendment for EXXUA™ for Treatment of Major Depressive Disorder
/PRNewswire/ -- Fabre-Kramer Pharmaceuticals, Inc. (Fabre-Kramer) today announced that on December 23, 2022, it filed an NDA Amendment with the Food and Drug...
Source: prnewswire.com